Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBT: 2016-2025

Historic EBT for Anaptysbio (ANAB) over the last 10 years, with Sep 2025 value amounting to $15.1 million.

  • Anaptysbio's EBT rose 146.00% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.6 million, marking a year-over-year increase of 48.96%. This contributed to the annual value of -$145.2 million for FY2024, which is 11.24% up from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's EBT is $15.1 million, which was up 139.16% from -$38.6 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's EBT ranged from a high of $15.1 million in Q3 2025 and a low of -$46.7 million during Q2 2024.
  • Moreover, its 3-year median value for EBT was -$39.3 million (2025), whereas its average is -$33.8 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 6,121.91% in 2022, then skyrocketed by 146.00% in 2025.
  • Quarterly analysis of 5 years shows Anaptysbio's EBT stood at -$31.1 million in 2021, then grew by 28.80% to -$22.1 million in 2022, then tumbled by 90.72% to -$42.2 million in 2023, then skyrocketed by 48.38% to -$21.8 million in 2024, then spiked by 146.00% to $15.1 million in 2025.
  • Its EBT was $15.1 million in Q3 2025, compared to -$38.6 million in Q2 2025 and -$39.3 million in Q1 2025.